As an industry, we work with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and Patient Organizations to develop cutting-edge technology that treats patients affected by rare and life-threatening neurological genetic diseases. We believe open and transparent communication about the work we do with these parties fosters an essential trust among patients, HCPs, and government officials. As a commitment to transparency, we publish payments or transfers of value to HCPs, HCOs and Patient Organizations who have worked with us to make progress in the treatment of neurological genetic diseases.

Please click here to visit the Global Transparency page listing the disclosure reports for each country.